Endothelin-1 downregulates Mas receptor expression in human cardiomyocytes

Molecular Medicine Reports

Volumn 8, Issue 3, 2013, Pages 871-876

  Chen, Zhiheng ^a   Tang, Yamei ^b   Yang, Zuocheng ^a   Liu, Shaojun ^b   Liu, Yong ^b   Li, Yan ^a   He, Wei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Angiotensin II; Angiotensin (1 7); Angiotensin converting enzyme 2; Cardiomyocytes; Endothelin A receptor; Endothelin 1; Mas receptor; P38 mitogen activated protein kinase

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 NITROPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DACTINOMYCIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; MAS RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA ANALYSIS;

CELLS, CULTURED; DACTINOMYCIN; DOWN-REGULATION; ENDOTHELIN-1; HUMANS; MYOCYTES, CARDIAC; OLIGOPEPTIDES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PEPTIDES, CYCLIC; PIPERIDINES; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, G-PROTEIN-COUPLED; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTION, GENETIC;

EID: 84881153481     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2013.1577     Document Type: Article

References (22)

1. Domenighetti AA, Wang Q, Egger M, Richards SM, Pedrazzini T and Delbridge LM: Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension 46: 426-432, 2005.
2. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR and Nussberger J: Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 35: 985-991, 2000.
3. Domenighetti AA, Ritchie M, Smyth G, Pedrazzini T, Proietto J and Delbridge LMD: Gene expression profiling reveals distinct sets of genes altered during hormonally and metabolically induced cardiac hypertrophies. J Mol Cell Cardiol 37: 303, 2004.
4. Ferreira AJ, Murça TM, Fraga-Silva RA, Castro CH, Raizada MK and Santos RA: New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens 2012: 147825, 2012.
5. Raizada MK and Ferreira AJ: ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol 50: 112-119, 2007.
6. Vickers C, Hales P and Kaushik V, et al: Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277: 14838-14843, 2002.
7. Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ and Raizada MK: ACE2: a novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol 91: 163-198, 2006.
8. Rice GI, Thomas DA, Grant PJ, Turner AJ and Hooper NM: Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383: 45-51, 2004.
9. Stanziola L, Greene LJ and Santos RA: Effect of chronic angiotensin converting enzyme inhibition on angiotensin I and bradykinin metabolism in rats. Am J Hypertens 12: 1021-1029, 1999.
10. Gomes ER, Santos RA and Guatimosim S: Angiotensin-(1-7)-mediated signaling in cardiomyocytes. Int J Hypertens 2012: 493129, 2012.
11. Ferreira AJ and Santos RA: Cardiovascular actions of angiotensin-(1-7). Braz J Med Biol Res 38: 499-507, 2005.
12. Zhang T, Li Z, Dang H, et al: Inhibition of Mas G-protein signaling improves coronary blood flow, reduces myocardial infarct size, and provides long-term cardioprotection. Am J Physiol Heart Circ Physiol 302: H299-H311, 2012.
13. Vignon-Zellweger N, Heiden S, Miyauchi T and Emoto N: Endothelin and endothelin receptors in the renal and cardiovascular systems. Life Sci 91: 490-500, 2012.
14. Shichiri M, Hirata Y, Ando K, et al: Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 15: 493-496, 1990.
15. Wei CM, Lerman A, Rodeheffer RJ, et al: Endothelin in human congestive heart failure. Circulation 89: 1580-1586, 1994.
16. Yazici M, Demircan S, Durna K and Sahin M: The relation between endothelin-1 levels and myocardial injury in chronic ischemic heart failure. Heart Vessels 20: 95-99, 2005.
17. Gironacci MM, Adamo HP, Corradi G, Santos RA, Ortiz P and Carretero OA: Angiotensin (1-7) induces MAS receptor internalization. Hypertension 58: 176-181, 2011.
18. Windischhofer W, Zach D, Fauler G, Raspotnig G, Köfeler H and Leis HJ: Involvement of Rho and p38 MAPK in endothelin-1-induced expression of PGHS-2 mRNA in osteoblast-like cells. J Bone Miner Res 17: 1774-1784, 2002.
19. Ohmae M: Endothelin-1 levels in chronic congestive heart failure. Wien Klin Wochenschr 123: 714-717, 2011.
20. Gallagher PE, Ferrario CM and Tallant EA: Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 295: H2373-H2379, 2008.
21. de Jonge HW, Dekkers DH, Houtsmuller AB, Sharma HS and Lamers JM: Differential signaling and hypertrophic responses in cyclically stretched vs endothelin-1 stimulated neonatal rat cardiomyocytes. Cell Biochem Biophys 47: 21-32, 2007.
22. Santos RA, Ferreira AJ, Verano-Braga T and Bader M: Angiotensin- converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin angiotensin system. J Endocrinol 216: R1-R17, 2013.